Pharming: 3 Key Takeaways for Long-Term Investors
A rare-disease player with a stabilized core product is now targeting a market 26 times larger, fueled by cash generation that needs no external financing.
Pharming reported a 21% increase in total revenue to $117.6 million for its third-quarter 2026 earnings, with operating profit rising 89% to $29.9 million due to expanded sales of its primary rare disease treatments. The company's strong cash generation allows it to fund clinical drug pipeline expansion without additional financing.
RUCONEST, a treatment for hereditary angioedema, returned to revenue growth after earlier declines and reached $93.8 million, up 14% year-over-year. Joenja, a therapy for activated phosphoinositide 3-kinase delta syndrome, saw international sales generate roughly one-third of its revenue, with new international launches and FDA pediatric approvals boosting its market presence.
Management is actively expanding into common variable immune deficiency and other high growth immunology markets, leveraging strong patient retention and specialized manufacturing to create durable competitive advantages. With $191 million in cash reserves and positive operating profit, Pharming appears well-positioned for long-term growth across broader immunology markets.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.